Yahoo Finance Outlook on the Inhaled Nitric Oxide Global Market to 2026 - Featuring Getinge, Merck and Halma Among Others
Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
The Global Inhaled Nitric Oxide Market size is expected to reach $915.7 Million by 2026, rising at a market growth of 7% CAGR during the forecast period. Nitric oxide is a molecule of gas that causes a sense of relaxation in smooth muscle cells in the vasculature. It is because Nitric Oxide reacts with oxyhemoglobin. The gas is quickly collected by oxyhemoglobin in red blood cells and the vasodilating effects caused by inhaled nitric oxide are restricted to oxygenated areas of the lungs. Thus, this distinct ability of Nitric oxide to cause pulmonary vasodilatation in the oxygenated regions of the lung helps in enhancing oxygenation of the blood and reduces intrapulmonary right to left shunting. Hence, the inhaled nitric oxide is utilized to cure various cardiopulmonary conditions, like pulmonary hypertension in adults and children. Although, the usage of inhaled nitric oxide is restricted due to logistical and financial reasons.
The rising prevalence of diseases in infants like a neonatal hypoxic respiratory failure (HRF) and persistent pulmonary hypertension is among the key driving factors of the market. Moreover, the growing number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) also propel the market growth. Apart from this, the huge cost involved in the treatment & the stringent government policies on different applications of the gas are restricting the growth of Inhaled Nitric Oxide market. However, the constant R&D activities for discovering various new applications in the healthcare sector are estimated to offer profitable opportunities for expanding the global inhaled nitric oxide market during the forecast period.
The declaration of WHO about the Covid-19 outbreak as a public health emergency has affected every country around the globe. During the pandemic, nitric oxide got under several experiments to test whether it can help in treating Covid-19 affected people, due to its antiviral properties and enhanced oxygenation. Inhaled Nitric Oxide is useful in safeguarding the frontline healthcare workers from this pandemic.
Application Outlook
Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Neonatal respiratory treatment segment procured the substantial revenue share and is estimated to exhibit high growth rate during the forecast period. This is due a surge in the occurrences of diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). The chronic obstructive pulmonary disease segment is expected to display promising growth rate during the forecast period.
Regional Outlook
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the global inhaled nitric oxide market in 2019. The high growth of the regional market is due to the large consumer base & rising funding in R&D by the leading players. Major determinants such as surge in rates of chronic diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF) are expected to support the market growth.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.
Unique Offerings from the Publisher
Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free
Key Topics Covered:
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Inhaled Nitric Oxide Market, by Application
1.4.2 Global Inhaled Nitric Oxide Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Inhaled Nitric Oxide Market
Chapter 4. Global Inhaled Nitric Oxide Market by Application
4.1 Global Neonatal Respiratory Treatment Repellent Market by Region
4.2 Global Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Region
4.3 Global Acute Respiratory Distress Syndrome (ARDS) Market by Region
4.4 Global Other Applications Market by Region
Chapter 5. Global Inhaled Nitric Oxide Market by Region
5.1 North America Inhaled Nitric Oxide Market
5.2 Europe Inhaled Nitric Oxide Market
5.3 Asia Pacific Inhaled Nitric Oxide Market
5.4 LAMEA Inhaled Nitric Oxide Market
Chapter 6. Company Profiles
6.1 Getinge AB
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Merck Group
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Halma PLC
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Linde PLC (Praxair, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Acquisition and Mergers:
6.5 Air Liquide S.A.
6.5.1 Company Overview
6.5.1 Financial Analysis
6.6 Beyond Air, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expense
6.6.4 Recent strategies and developments:
6.6.4.1 Trials and Approvals:
6.7 Mallinckrodt PLC (International Minerals and Chemical Corporation)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Trials and Approvals:
6.7.5.2 Partnerships, Collaborations, and Agreements:
6.8 VERO Biotech LLC
6.8.1 Company Overview
6.8.2 Recent strategies and developments:
6.8.2.1 Trials and Approvals:
6.9 Nu-Med Plus, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, Collaborations, and Agreements:
6.10. Novoteris, LLC
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Trials and Approvals:
For more information about this report visit https://www.researchandmarkets.com/r/4lwdu9
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
